The joint pain injections market involves drugs and therapies administered via injections into joints affected by conditions like arthritis to reduce pain and disability. Common types of joint injections include corticosteroids, viscosupplements, and hyaluronic acid. Corticosteroids work by reducing inflammation and pain by modifying the immune response. They provide short-term relief but come with side effects with prolonged use. Hyaluronic acid and viscosupplements act as lubricants and supplements within the joint, protecting cartilage and improving joint fluid viscosity. Their effects last longer with fewer side effects. The demand for joint pain injections is rising with the growing geriatric population who are more prone to joint disorders.

The Global joint pain injections market is estimated to be valued at US$ 9.46 Bn in 2024 and is expected to exhibit a CAGR of 8.7% over the forecast period from 2024 to 2031.

Key Takeaways

Key players operating in the Joint Pain Injections Market Growth  are Pfizer, Inc., Ferring Pharmaceuticals Inc., PACIRA BIOSCIENCES, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Sanofi, Anika Therapeutics, Inc., Bioventus, Dr. Reddy’s Laboratories Ltd., Zimmer Biomet, Ferring B.V., SEIKAGAKU CORPORATION, and Ono Pharmaceutical Co., Ltd. These companies are focusing on expanding their product portfolios and global presence through acquisitions and partnerships.

The growing demand for palliative care across both developed and developing markets is a major driver of market growth. With joint disorders affecting a significant proportion of elderly populations worldwide, the need for effective but less invasive pain management therapies is increasing rapidly. Several clinical trials are also being conducted to evaluate long-acting injectable drugs with the potential for reduced frequency of dosing.

Get More Insights On This Topic: Joint Pain Injections Market